These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 26576135)

  • 1. Pharmacologic Agents for Chronic Diarrhea.
    Lee KJ
    Intest Res; 2015 Oct; 13(4):306-12. PubMed ID: 26576135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine.
    Lee KJ; Kim NY; Kwon JK; Huh KC; Lee OY; Lee JS; Choi SC; Sohn CI; Myung SJ; Park HJ; Choi MK; Bak YT; Rhee PL
    Neurogastroenterol Motil; 2011 Dec; 23(12):1098-104. PubMed ID: 21920001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Therapies in IBS-D Treatment.
    Nee J; Zakari M; Lembo AJ
    Curr Treat Options Gastroenterol; 2015 Dec; 13(4):432-40. PubMed ID: 26432092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
    Rivkin A; Rybalov S
    Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D).
    Min YW; Rhee PL
    Therap Adv Gastroenterol; 2015 May; 8(3):136-42. PubMed ID: 25949526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chronic, non-infectious diarrhea: diagnostics and therapy].
    Ulbricht K; Layer P; Andresen V
    Dtsch Med Wochenschr; 2016 Sep; 141(19):1395-402. PubMed ID: 27642742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current gut-directed therapies for irritable bowel syndrome.
    Chang HY; Kelly EC; Lembo AJ
    Curr Treat Options Gastroenterol; 2006 Jul; 9(4):314-23. PubMed ID: 16836950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of irritable bowel syndrome with diarrhea: a review of nonpharmacological and pharmacological interventions.
    Cangemi DJ; Lacy BE
    Therap Adv Gastroenterol; 2019; 12():1756284819878950. PubMed ID: 31632456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?
    Cash BD; Lacy BE; Rao T; Earnest DL
    Expert Opin Pharmacother; 2016; 17(3):311-22. PubMed ID: 26559529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii.
    Bafutto M; Almeida JR; Leite NV; Costa MB; Oliveira EC; Resende-Filho J
    Arq Gastroenterol; 2013; 50(4):304-9. PubMed ID: 24474234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea.
    Fukudo S; Ida M; Akiho H; Nakashima Y; Matsueda K
    Clin Gastroenterol Hepatol; 2014 Jun; 12(6):953-9.e4. PubMed ID: 24315882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials.
    Qi Q; Zhang Y; Chen F; Zuo X; Li Y
    BMC Gastroenterol; 2018 Jan; 18(1):5. PubMed ID: 29310568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A practical approach to treating patients with chronic diarrhea.
    Sellin JH
    Rev Gastroenterol Disord; 2007; 7 Suppl 3():S19-26. PubMed ID: 18192962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis.
    Martínez-Vázquez MA; Vázquez-Elizondo G; González-González JA; Gutiérrez-Udave R; Maldonado-Garza HJ; Bosques-Padilla FJ
    Rev Gastroenterol Mex; 2012; 77(2):82-90. PubMed ID: 22672854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women.
    Fukudo S; Kinoshita Y; Okumura T; Ida M; Akiho H; Nakashima Y; Nishida A; Haruma K
    Gastroenterology; 2016 Feb; 150(2):358-66.e8. PubMed ID: 26551550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modern Management of Irritable Bowel Syndrome: More Than Motility.
    Tack J; Vanuytsel T; Corsetti M
    Dig Dis; 2016; 34(5):566-73. PubMed ID: 27331917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Guidelines for the treatment of irritable bowel syndrome].
    Kwon JG; Park KS; Park JH; Park JM; Park CH; Lee KJ; Park HJ; Rhee JC;
    Korean J Gastroenterol; 2011 Feb; 57(2):82-99. PubMed ID: 21350320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.
    Nee J; Zakari M; Lembo AJ
    Expert Opin Pharmacother; 2015; 16(18):2781-92. PubMed ID: 26558923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs for Irritable Bowel Syndrome.
    Med Lett Drugs Ther; 2020 Mar; 62(1594):25-32. PubMed ID: 32324172
    [No Abstract]   [Full Text] [Related]  

  • 20. Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea.
    Pimentel M
    Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():37-49. PubMed ID: 26618924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.